Roivant Sciences employs a unique business model that focuses on the creation of specialized companies, referred to as "Vants," to drive the discovery, development, and commercialization of innovative medicines. This model allows Roivant to align incentives effectively, ensuring rapid and high-quality execution in their projects. The company has successfully conducted numerous Phase 3 clinical trials across various therapeutic areas, demonstrating its commitment to advancing transformative therapies. Their pipeline includes a diverse range of investigational drugs, showcasing their agnostic approach to therapeutic modalities and areas, which enables them to explore multiple avenues for medical advancement.

The technologies utilized by Roivant Sciences span the entire spectrum of drug development, from discovery to commercialization. They leverage advanced methodologies in clinical trial design and execution, which have led to significant achievements, including multiple FDA approvals and successful trial outcomes. Their subsidiaries, such as Immunovant and Dermavant, focus on specific therapeutic areas like autoimmune diseases and immuno-dermatology, respectively, further highlighting Roivant's strategy of fostering specialized expertise within its Vants. This approach not only enhances the efficiency of drug development but also positions Roivant to address unmet medical needs effectively.

United States

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology.

The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. 

In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.

Cancer

Endocrine System Diseases

Eye Diseases

Hematologic Diseases

Immune System Diseases

Nervous System Diseases

Skin Diseases

Roivant Sciences

Psoriasis

VTAMA (Tapinarof)

Atopic dermatitis

Ulcerative colitis

RVT-3101

Chronic non-infectious uveitis

Dermatomyositis

Systemic lupus erythematosus

Brepocitinib

Eye disease

Thyroid Eye Disease

Batoclimab

Myasthenia gravis

Brepocitinib 

Crohns disease

RVT-3101 

Pulmonary hypertension associated with interstitial lung disease

Mosliciguat

Sarcoidosis

Myelodysplastic syndrome

RVT-2001

Namilumab

New York

Adeno-associated viral vector (AAV)

Biologics

Cell Therapies

Gene Therapy

Lentiviral Vector (LVV)

Small Molecule Pharmaceuticals

Therapeutic

Roivant Sciences

Company Details